The Technical Analyst
CV Sciences, Inc. [CVSI]
Exchange: PNK Industry: Drug Manufacturers
CV Sciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
13.84% $0.0440
America/New_York / 3 mai 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.18 mill |
| EPS: | 0.0200 |
| P/E: | 2.20 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 163.23 mill |
| Avg Daily Volume: | 0.277 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 2.20 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 2.20 | industry: PE -6.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0390 - 0.0490 ( +/- 11.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-15 | Dowling Joseph D | Buy | 2 500 000 | Employee Stock Option (right to buy) |
| 2023-03-15 | Grasser Joerg | Buy | 1 250 000 | Employee Stock Option (right to buy) |
| 2022-10-21 | Mccorkle William | Buy | 500 000 | Employee Stock Option (right to buy) |
| 2022-10-21 | Mccorkle William | Buy | 0 | |
| 2022-10-21 | Mccorkle William | Buy | 0 |
| INSIDER POWER |
|---|
| 100.00 |
| Last 97 transactions |
| Buy: 17 580 526 | Sell: 13 733 278 |
Forecast:
16:00 - $0.0440
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0440
Forecast 2: 16:00 - $0.0440
Forecast 3: 16:00 - $0.0440
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0440 (13.84% ) |
| Volume | 0.242 mill |
| Avg. Vol. | 0.277 mill |
| % of Avg. Vol | 87.38 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CVSI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CVSI
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Latest Press Releases
2024-03-28 09:00:00 - Press Release
Cv Sciences, Inc. Reports Fiscal Year-end 2023 Financial Results
San diego , march 28, 2024 /prnewswire/ -- cv sciences, inc. (otcqb:cvsi) (the "company", "cv sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended december 31, 2023. fiscal 2023, fourth quarter 2023 and recent financial and operating highlights generated revenue of $16.0 million for fiscal 2023 compared to $16.2 million for 2022; revenue of $3.8 million for the fourth quarter 2023 compared to $4.1 million in the third quarter 2023; recognized gross margin of 44.3% for fiscal year 2023, a significant improvement from 34...
2024-03-26 08:00:00 - Press Release
Cv Sciences, Inc. Expands +pluscbd Pet Product Offerings With The Launch Of Pet Chews
Pet hip and joint health chews and pet calming care chews improve the physical and emotional well-being of dogs san diego , march 26, 2024 /prnewswire/ -- cv sciences, inc. (otcqb: cvsi) (the "company", "cv sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier cbd chew tailored for pets, +pluscbd™ pet hip and joint health chews and +pluscbd™ pet calming care chews. +pluscbd™pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the national animal supplement council (nasc).
2024-03-21 09:00:00 - Press Release
Cv Sciences, Inc. To Announce Year End And Fourth Quarter 2023 Results On March 28, 2024
San diego , march 21, 2024 /prnewswire/ -- cv sciences, inc. (otcqb: cvsi) (the "company", "cv sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in nutraceuticals and plant-based foods, today announced that it will release financial results for the year and fourth quarter ended december 31, 2023, before the stock market opens on thursday, march 28, 2024. the company will hold a conference call with the investment community at 7:00 a.m.
2023-12-12 08:00:00 - Press Release
Cv Sciences, Inc. Acquires Cultured Foods To Enter Plant-based Food Market, Opening Door For European Distribution
San diego , dec. 12, 2023 /prnewswire/ -- cv sciences, inc. (otcqb:cvsi) (the "company", "cv sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has consummated its purchase of cultured foods , a leading manufacturer and distributor of alternative plant-based vegan foods. cultured foods produces a variety of curated plant-based products, currently sold in 15 different european countries, with its base of operations in warsaw, poland.
2023-11-14 09:00:00 - Press Release
Cv Sciences, Inc. Reports Third Quarter 2023 Financial Results
San diego , nov. 14, 2023 /prnewswire/ -- cv sciences, inc. (otcqb:cvsi) (the "company", "cv sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended september 30, 2023. third quarter 2023 and recent financial and operating highlights increased revenue to $4.1 million for the third quarter 2023 compared to $3.8 million for the third quarter 2022 and a sequential improvement from $4.0 million for the second quarter 2023; recognized gross margin of 45.1% for the third quarter 2023 compared to 41.6% for the third quarter 2022 and a sequential improvement from 43...
Latest News
2023-11-14 14:07:06 - Seeking Alpha
CV Sciences, Inc. (CVSI) Q3 2023 Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q3 2023 Earnings Conference Call November 14, 2023 10:00 AM ET Company Participants Brendan Hawkins - Investor Relations Joseph Dowling - Chief Executive Officer Joerg Grasser - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the CV Sciences, Inc. Third Quarter 2023 Conference Call. [Operator Instructions] Please note this event is being recorded.
2023-08-14 13:30:19 - Seeking Alpha
CV Sciences, Inc. (CVSI) Q2 2023 Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q2 2023 Earnings Conference Call August 14, 2023 10:00 AM ET Company Participants Brendan Hawkins - IR Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Operator Hello, and welcome to the CV Sciences, Inc. Second Quarter 2023 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-05-15 12:09:10 - Seeking Alpha
CV Sciences, Inc. (CVSI) Q1 2023 Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q1 2023 Earnings Conference Call May 15, 2023 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary and Director Joerg Grasser - CFO Conference Call Participants Operator Greetings. And welcome to the CV Sciences, Inc. First Quarter 2023 Conference call.
2023-03-29 13:32:06 - Seeking Alpha
CV Sciences, Inc. (CVSI) Q4 2022 Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q4 2022 Earnings Call Transcript March 29, 2023 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary and Director Joerg Grasser - CFO Conference Call Participants Operator Greetings. And welcome to the CV Sciences' Fourth Quarter and Year End 2022 Conference call.
2023-03-24 20:00:00 - PRNewsWire
CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2022 RESULTS ON MARCH 29, 2023
SAN DIEGO , March 24, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year and fourth quarter ended December 31, 2022, before the stock market opens on Wednesday, March 29, 2023. The Company will hold a conference call with the investment community at 7:00 a.m.
2022-11-14 12:10:27 - Seeking Alpha
CV Sciences, Inc. (CVSI) Q3 2022 Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q3 2022 Earnings Conference Call November 14, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference Call Participants Greetings, and welcome to the CV Sciences Third Quarter 2020 Conference Call. [Operator Instructions].
2022-08-15 13:55:04 - Seeking Alpha
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q2 2022 Results - Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q2 2022 Earnings Conference Call August 15, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference Call Participants Operator Greetings, and welcome to the CV Sciences Second Quarter 2020 Conference Call. [Operator Instructions].
2022-05-16 12:37:11 - Seeking Alpha
CV Sciences, Inc. (CVSI) CEO Joseph Dowling on Q1 2022 Results - Earnings Call Transcript
CV Sciences, Inc. (OTCQB:CVSI) Q1 2022 Results Conference Call May 16, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Scott Fortune - ROTH Capital Operator Greetings. Welcome to the CV Sciences First Quarter 2022 Conference Call.
2022-03-28 16:05:00 - GlobeNewsWire
CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022
SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
2022-01-11 13:59:45 - Benzinga
Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in Dry January. Who Thought Of Laying Off Booze For A Month?